Influenza B is just as severe as influenza A in hospitalized adults, causing comparable rates of ICU admission, length of hospital stay, and death. The perception that influenza B is a “milder” flu is outdated. While it circulates less frequently than influenza A, it hits just as hard when it does.
How Influenza B Compares to Influenza A
A CDC study analyzing nearly 25,000 flu-related hospitalizations found no significant difference in severity between influenza A and influenza B among adults. Patients hospitalized with B were admitted to the ICU at the same rate as those with A, stayed in the hospital just as long, and died at a similar rate. The main difference is volume: influenza A causes far more total infections each season because it mutates faster and has more subtypes circulating at any given time. But infection for infection, influenza B is equally dangerous.
Influenza B does tend to peak later in the flu season, often in February or March in the Northern Hemisphere, which sometimes gives the impression it’s an afterthought. It’s not. In some seasons, influenza B becomes the dominant strain and drives a second wave of hospitalizations after influenza A activity has faded.
Symptoms and Recovery Timeline
Influenza B produces the same symptoms as influenza A: sudden fever, body aches, sore throat, cough, headache, and fatigue. There’s no reliable way to distinguish between A and B based on how you feel. Both come on quickly, typically within one to four days after exposure.
For most otherwise healthy people, the worst of the illness resolves within about a week without antiviral treatment. However, the cough and a lingering sense of fatigue can stick around for two weeks or longer, especially in older adults. You’re most contagious during the first three to four days after symptoms appear, particularly if you have a fever.
Complications Worth Knowing About
The most common serious complication is pneumonia, which can develop from the flu virus alone or from a bacterial infection that moves in while the immune system is occupied fighting the flu. Beyond the lungs, influenza B can trigger inflammation of the heart muscle, the brain, or skeletal muscle tissue. In rare cases, the infection provokes an overwhelming immune response that leads to sepsis or multi-organ failure involving the lungs and kidneys.
These complications aren’t unique to influenza B. They occur with influenza A at similar rates. But they’re a reminder that the flu, regardless of type, is not just a bad cold. People over 65, young children, pregnant women, and anyone with chronic heart, lung, or immune conditions face the highest risk of these outcomes.
Risks for Children
Influenza B poses a particular concern for kids. While influenza A causes the majority of pediatric flu deaths in most seasons (about 86% in recent surveillance data), influenza B punches above its weight relative to how widely it circulates. Children and adolescents make up a larger share of severe influenza B cases compared to adults.
During the 2024-25 season, 56% of children who died from flu-related causes had underlying conditions that put them at higher risk for severe illness, such as asthma or neurological disorders. That also means 44% of pediatric flu deaths occurred in children who were previously healthy. In two past flu seasons (2012-13 and 2019-20), influenza B actually caused more pediatric deaths than influenza A, a striking reversal of the usual pattern.
What’s Happened to the B Lineages
Influenza B used to circulate as two distinct lineages: Victoria and Yamagata. This is why flu vaccines were reformulated as quadrivalent (four-component) shots, covering both B lineages plus two influenza A subtypes. That changed recently. The Yamagata lineage has not been reliably detected in circulation since early 2020 and is now considered likely extinct. The handful of cases reported since then have been traced to vaccine-derived detections or data entry errors.
In response, the WHO recommended dropping the Yamagata component from flu vaccines starting with the 2024-25 Northern Hemisphere season. Current vaccines now target only the B/Victoria lineage. This simplification doesn’t reduce your protection since Yamagata no longer appears to be a threat.
How Well the Vaccine Works Against Influenza B
The flu vaccine actually performs better against influenza B than against influenza A in most seasons. Recent CDC estimates for the 2025-26 season showed vaccine effectiveness against influenza B outpatient visits was 63% among adults. For children and adolescents, effectiveness ranged from 45% to 71% depending on the surveillance network measuring it.
By comparison, vaccine effectiveness against influenza A in the same season was only about 34% for adults. Influenza A mutates more aggressively, making it a harder target for vaccine designers. The relative stability of influenza B means the vaccine match tends to be closer, translating to better real-world protection. Even when the vaccine doesn’t prevent infection entirely, it consistently reduces the risk of hospitalization and severe outcomes.